For the NHS
For business
Solutions
Science
Clinicians
Investors
About Us
Careers
Get in touch
FacebookTwitterLinkedinYouTube

Stephen Bruso

The Board

Stephen Bruso joined the Morningside investment team in 2019 and focuses on investments in both the biopharma and digital health fields. He has extensive experience providing operational and management oversight to early-stage companies. Mr. Bruso serves as a director for numerous private companies including Cognito Therapeutics, Curai, Suvera, Vesigen Therapeutics, Neuroelectrics, Innodem Neurosciences, Manistee Therapeutics, MedRhythms, Huckleberry, Ieso Digital Health, Wellinks, and DeepCure; he is a board observer at Linus Health.

Prior to joining Morningside, Mr. Bruso worked at a series of molecular diagnostics startups spun out from the Church Lab at HMS before co-leading the development and launch of cloud software products at an e-commerce startup. He received his MBA from Boston University in 2019, graduating magna cum laude. He received hisBA from Emory University in 2009.

Dr Nigel Pitchford

Chief Executive Officer

Dr Valentin Tablan

Chief Artificial Intelligence Officer

Dr Andy Blackwell

Group Chief Science & Strategy Officer

Dr Andy Blackwell

Group Chief Science & Strategy Officer

Stephen Freer

EVP Clinical

Dr Charlotte Housden

Chief Operating Officer

Michael Black

Chief Financial Officer

Dani Smallbone

Chief Marketing Officer

Kate Woolland

Chief Partnerships Officer

James Kellerman

Chief Technology Officer

Dr Valentin Tablan

Chief Artificial Intelligence Officer

Dr Jennifer Gentile

SVP US Clinical Operations

Lynn Lakey

Interim Managing Director

Chris Kightley

Interim Managing Director

Dr Andrew Welchman

Executive Vice President for Impact

Danah Tangen

Chief of Staff